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ABSTRACT
Introduction: The objective of the study was to
determine the relative importance (RI) of treat-
ment attributes psoriasis patients and physi-
cians consider when choosing between biologic
therapies based on psoriasis severity.
Methods: A discrete choice experiment (DCE)
weighting preference for eight sets of hypo-
thetical treatments for moderate or severe pso-
riasis was conducted. DCE hypothetical
treatments were defined and varied on combi-
nations of efficacy, safety, and dosing attributes
[frequency/setting/route of administration
(ROA)].
Results: When assuming moderate psoriasis in
the patient DCE, ROA (RI 29%) and efficacy (RI
27%) drive treatment choices. When assuming
severe disease in the DCE, patients preferred
treatments with higher efficacy (RI 36%); ROA
was relatively less important (RI 15%). From the
physician perspective, ROA (RI 32%) and effi-
cacy (RI 26%) were most important for moder-
ate psoriasis patients. In the physician model
for severe psoriasis, efficacy (RI 42%) was the
predominant driver followed by ROA (RI 22%).
Regardless of severity, probability of loss of
response within 1 year was the least important
factor.
Conclusions: The severity of disease is a critical
element in psoriasis treatment selection. There
are high levels of alignment between physician-
and patient-derived preferences in biologic
treatment choice selection for psoriasis.
Funding: Janssen Pharmaceuticals.
Keywords: Biologic treatment selection;
Discrete choice experiment; Moderate severe
psoriasis; Patients and physician DCE
INTRODUCTION
Psoriasis is a chronic, systemic, autoimmune
disease that affects the skin and may be associ-
ated with other inflammatory conditions and
comorbidities. The prevalence of diagnosed
psoriasis has previously been estimated to range
from 0.5% to 3.15% of the adult population in
the USA, with the most common form being
plaque psoriasis [1–5]. The burden of psoriasis is
substantial, with negative physical, emotional,
and psychosocial implications for patients’
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quality of life [6]. This burden is particularly
large among adults with moderate to severe
disease, a subgroup representing approximately
18% of the overall psoriasis population [1]. The
sizeable disease burden in moderate to severe
psoriasis is reflected in the incremental annual
total healthcare ($18,960 per patient), medical
($13,990 per patient), and pharmacy ($3895 per
patient) expenditures for this population [7].
The treatment paradigm for psoriasis has
evolved with the emergence of biologic thera-
pies targeting specific cytokines in the inflam-
matory cascade driving disease pathogenesis.
Current therapeutic strategies vary by disease
severity and other patient-specific factors, with
available treatments comprising topical thera-
pies, phototherapies, and systemic agents,
which include conventional and newer oral
agents, as well as biologics that can be admin-
istered through subcutaneous injection (subQ)
or intravenous infusion (IV) [8]. Clinical trial
data suggest superior efficacy with biologic
agents compared with conventional systemic
agents [9]; long-term observational data indi-
cate a consistent and reassuring safety profile
based on the collective body of evidence to date
compared with conventional systemic medica-
tions [10].
Despite improved efficacy, safety profile, and
adherence to therapy among patients on bio-
logics compared to those on systemic therapies
[9], utilization of biologic agents remains low. A
2012 survey found that only 8% of moderate to
severe psoriasis patients reported use of biologic
therapy while dermatologists estimated that
about 36% of this patient population was trea-
ted with biologics. These findings suggest that
there are discordant perceptions of disease
severity and underutilization of dermatologist
services by moderate to severe patients. Fur-
thermore, 31% of moderate to severe psoriasis
patients reported that their primary goals of
treatment were not met by their current treat-
ment [11]. Several reasons for underutilization
of biologics have been cited by physicians,
including managed care utilization controls,
unaffordable out-of-pocket costs for patients,
and perceived lack of adequate long-term safety
data by prescribers.
Psoriasis assessments (e.g., PGA, PASI) tend
to be physician-centric, which may further
obscure patients’ perception of disease burden
and preferred treatment attributes. Further-
more, differences in how patients and physi-
cians evaluate benefits and risks of therapies
emphasize the importance of shared deci-
sion-making when selecting a psoriasis treat-
ment [12, 13]. Shared decision-making has been
shown to beneficially influence patient satis-
faction, treatment compliance, and ultimately
health outcomes [14–17].
Further studies are needed to better under-
stand physician and patient preferences around
choice of therapy. Discrete choice experiments
(DCE) are used to quantify preferences for
therapies or services where various elements
may limit choices. DCEs have been used for this
purpose in a broad range of therapeutic areas in
health care. The choice task requires respon-
dents to make trade-offs (akin to real-world
decision-making) between various treatment
attributes and levels in determining their over-
all treatment preferences. Previous DCEs in
psoriasis have evaluated either physician [17] or
patient [18–20] preferences for treatment attri-
butes, without direct comparison between
stakeholders. In this study, the relative impor-
tance of clinical attributes of biologics and
novel oral therapies that dermatologists and
psoriasis patients consider in choosing treat-
ments are quantified, and similarities and dif-
ferences in attribute prioritization by
dermatologists and patients are compared.
METHODS
Survey Instruments
To address the objectives of this study, we
developed physician and patient survey instru-
ments using DCE methodology. The physician
and patient survey instruments had parallel
designs to allow for comparison of treatment
attributes across the stakeholders. In addition to
the DCE, the surveys collected data on respon-
dent demographics, stated preferences for
psoriasis treatments, the impact of physi-
cian–patient relationship on therapy choice, as
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well as physician and patient attitudes towards
aspects of treatment decisions. Each survey
instrument took approximately 30 min to
complete.
Stated importance was measured on a Likert
scale of 1–9, with a score of 1 representing not at
all important and a score of 9 representing
extremely important. The scale was set to
9 points to allow for more gradation in ratings
of attribute importance to discern differences
between choices.
To enhance comprehension and to establish
a consistent baseline of disease severity, the
patient survey included reference pictures
showing a visual representation of body surface
area (BSA) affected by psoriasis (Fig. 1).
Both the physician and patient survey
instruments and treatment choice sets were
submitted to the University of Mississippi’s
Institutional Review Board (IRB), which deter-
mined the study to be exempt from review.
The surveys were also pretested with two der-
matologists and one patient with psoriasis to
ensure the relevance of the content, compre-
hensiveness of response options, and
user-friendliness of the survey. All procedures
followed were in accordance with the ethical
standards of the responsible committee on
human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013.
Discrete Choice Experiment
Two separate DCE surveys, each containing a
series of eight treatment choice questions,
were used for patients with either moderate or
severe psoriasis. Each choice set had three
hypothetical treatments with varying levels
within attributes from which respondents
selected. Dermatologists and patients with
moderate or severe psoriasis were asked to
choose which of the three treatments they
would select to treat moderate psoriasis and
then which of the three they would select to
treat severe psoriasis on the basis of the attri-
butes provided in the survey for each hypo-
thetical therapy.
The design and analysis of this study fol-
lowed published DCE guidelines [17, 18].
Attributes and Levels Tested in DCE
Package inserts, clinical literature, and consul-
tation with key opinion leaders (KOLs)
informed the choice of attributes and levels for
each attribute for hypothetical treatments.
Efficacy and safety data for current and devel-
oping biologic treatments for psoriasis were
used to design the attributes and levels tested in
the DCE. Specific attributes consisted of proba-
bility of improvement in psoriasis plaques as
measured by the psoriasis area severity index
Fig. 1 Visual representation of body surface area affected by psoriasis (illustrative example of patient survey)
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(PASI) and percentage of body surface area (BSA)
that remains affected 16 weeks after treatment
initiation; probability that dermatology life
quality index (DLQI) score will improve
16 weeks after treatment initiation; probability
of loss of response within 1 year; probability of
stopping therapy within 1 year for non-efficacy
reasons; probability of an adverse event (AE;
e.g., infection, headache, nausea); probability of
a severe AE (e.g., serious infection, malignancy);
and dosing (route of administration [ROA],
setting, and frequency). Ranges for levels of
potential outcomes were selected to span those
that could be expected to be achieved by cur-
rently available biologic and new oral treat-
ments. Probability of improvement in PASI and
% of BSA remaining are correlated so this was
included as one variable. To reduce the number
of attributes tested, dosing- and frequency-re-
lated variables (dosing, route of administration,
setting, and dosing frequency) were collapsed
into one attribute. Pretests with physicians and
patients validated understanding of attributes
and levels tested in the DCE. Table 1 shows the
set of attributes and ranges of levels of potential
outcomes tested in the DCE for physicians and
the corresponding language used for patients.
Experimental Design
Ideally, every combination of treatment attri-
butes would be shown to respondents, but
given our intention to align attribute combi-
nations with those of marketed products and
the sheer number of potential combinations,
this was not feasible. Therefore, experimental
design techniques were used to select the
specific number of choice sets, the number of
treatments presented in each choice set, and
which attribute levels should be shown within
each choice set. Specifically, choice model
design autocall macros %mktruns, %mktex, and
%mkteval were used in SAS 9.4 (Cary, NC, USA)
[21]. The %mktruns macro suggests possible
design sizes, the %mktex macro creates a design
with the maximum D-efficiency (to maximize
the precision of the estimated parameters), and
the %mkteval macro is used to evaluate the
design.
We restricted the experimental design from
showing currently implausible combinations
(e.g., for an oral product which met the
highest levels of effectiveness based on PASI
and BSA). In addition, we added a restriction
that a product could not have both the
highest levels of effectiveness for PASI and
BSA measures as well as the lowest levels of
probability for a serious adverse event (SAE).
This restriction was intended to prevent the
creation of a choice set for a treatment that
would be chosen with little variation across
respondents.
In this study, 16 choice sets, each containing
three hypothetical treatments, were created.
Each respondent saw a random set of eight
choice sets to reduce respondent fatigue. Two
treatment selections were made per choice set
by each patient; the selection was based upon
an assumption of treating either moderate or
severe psoriasis. Figure 2 shows an illustrative
choice set from which patient respondents had
to choose.
Study Recruitment
Physician respondents were recruited via email
invitation from an independent global panel
company with a national panel of at least
6 million members from across the USA. The
email invitation was not specific to the topic of
interest to minimize self-selection or introduce
bias into the survey.
Physician respondents were required to be
able to read English and were screened to
ensure they both specialize in and are
board-certified/board-eligible in dermatology,
have been in practice for 3–29 years, actively
treat at least 25 unique psoriasis patients in a
typical month, see at least eight moderate to
severe psoriasis patients in a typical month,
treat at least 20% of their moderate to severe
psoriasis with biologics, and are not employed
by a market research or advertising firm, or a
pharmaceutical or medical equipment
manufacturer.
Psoriasis patient respondents were recruited
through two consumer/patient panels with a
combined reach of at least 12.5 million
466 Dermatol Ther (Heidelb) (2017) 7:463–483
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members. The panel companies are indepen-
dent and have access to national panels of
consumers/patients residing across the USA.
Similar to physician recruitment, an email
invitation was sent to the consumer/patient
panel. The email invitation did not specify the
topic of interest to minimize self-selection into
the survey.
Psoriasis patient respondents were required
to be able to read English and were screened to
ensure they were adults (at least 18 years old),
had moderate to severe psoriasis based on
self-report of symptoms, and were not
employed by a market research or advertising
firm, or a pharmaceutical or medical equipment
manufacturer.
Data Cleaning Protocol
Respondents were removed from the DCE if
response patterns indicated lack of
thoughtfulness, including short survey duration
(\10 min) and straight-lining through several
batteries of questions.
Statistical Analyses
Data from the DCE were analyzed with a
multinomial logit model using PROC PHREG in
SAS 9.4 (Cary, NC, USA). While the first choice
is captured in the data, the second choice is
unobserved in our design. Therefore, the
unchosen treatment profiles are treated as cen-
sored values as in survival analyses. Effects
coding was used to keep interpretation of results
clear, consistent with previous DCE literature,
and such that all levels of the attributes can be
estimated [21].
The equation for the jth choice task is as
follows:
Fig. 2 Example of a choice set (DCE tested among patient respondents)
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uj ¼ x11jb11j þ x12jb12j þ x13jb13j þ x21jb21j
þ x22jb22j þ x23jb23j þ x24jb24j þ x25jb25j
þ x31jb31j þ x32jb32j þ x33jb33j þ x41jb41j
þ x42jb42j þ x43jb43j þ x51jb51j þ x52jb52j
þ x53jb53j þ x61jb61j þ x62jb62j þ x71jb71j
þ x72jb72j þ ej
where u is the perceived utility, xiyj is the yth
level of the ith attribute in the jth choice task,
biyj is the weight for the yth level of the ith
attribute in the jth choice task, and ej is the error
component.
Note: Highest levels of each attribute were
specified as the reference category.
Relative importance values, which reflect the
strength of influence that tested attributes have
on patient choice, were calculated as percent-
ages that combined totaled 100%. Relative
importance was calculated as percentages based
on the difference between the highest and
lowest coefficient values for each attribute
divided by the sum of the coefficient differences
between the highest and lowest levels across all
attributes, multiplied by 100.
RESULTS
Physician Recruiting and Clinical
Characteristics
The panel company sent email invitations to
about 3400 unique members. Of these, 400
physicians clicked on the link to start the survey
(response rate = 12%). Of those, 203 qualified
and completed the survey, but three respon-
dents were removed through data cleaning
procedures. Hence, the final physician sample
size used in the analysis was 200.
Table 2 summarizes descriptive statistics for
the 200 dermatologists included in the final
analysis. On average, sampled dermatologists
had about 14 years in clinical practice and
treated 114 unique psoriasis patients in a typical
month, with 48% of these patients having
moderate and 30% having severe psoriasis.
Eighty-six percent of sampled dermatologists
worked in a private office setting.
Patient Recruiting and Demographics
The panel companies sent email invitations to
about 50,000 unique panel members. Of these,
5500 respondents clicked on the link to start the
survey (response rate = 11%). Of those, 318
qualified and completed the survey and 122
were removed through data cleaning proce-
dures. The final patient sample size used in the
analysis was 196.
Table 3 summarizes the demographic and
disease characteristics of sampled psoriasis
Table 2 Demographic and clinical characteristics of par-
ticipating dermatologists
Sampled
dermatologists
(n 5 200)a
Years in practiceb 13.7 (7.8)
Total number of psoriasis patients
treated in a typical monthb
113.5 (136.1)
Mild psoriasis patients seen in a typical
month
35.3 (36.1)
Moderate psoriasis patients seen in a
typical month
47.7 (68.9)
Severe psoriasis patients seen in a
typical month
30.4 (45.4)
% of moderate to severe psoriasis
patients on biologicsb
55.8 (21.6)
Setting of primary practice
Private ofﬁce 171 (85.5%)
Community hospital 4 (2.0%)
Academic/teaching hospital 25 (12.5%)
Location of primary practice
Urban 80 (40.0%)
Suburban 114 (57.0%)
Rural 6 (3.0%)
Male 122 (61.0%)
a Values are count or mean (% or standard deviation)
b The range of this variable is impacted by screening cri-
teria for participation
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patients. By design, the sample consisted of
patients of most age, gender, and disease
severity combinations. Of the sampled psoriasis
patients, 45% reported having had moderate
psoriasis and 55% reported having had severe
psoriasis when their disease was at its worst.
Sixty percent of sampled psoriasis patients were
female, 42% of patients were 30–39 years of age,
and 79% were non-Hispanic white. Patients
reported that they were on the following treat-
ments at the time they completed the survey:
17% adalimumab, 16% etanercept, 9% inflix-
imab, 8% ustekinumab, 8% apremilast, and 6%
secukinumab.
Stated Importance of Attributes:
Physicians
Physician-stated treatment attribute preferences
for moderate and severe psoriasis were largely
similar (maximum difference in mean ratings of
0.3) (Table 4). The distributions of mean ratings
across moderate and severe psoriasis and across
treatment attributes were largely on the middle
to high end of the 9-point scale ([6). Overall
safety (mean score of 8.1) and low potential for
AEs in real-world use (mean score of 8.0) were
the highest rated attributes for both moderate
and severe psoriasis, while reduction in BSA
affected after 16 weeks of treatment was also
rated highly (mean score of 8.0) for treating
severe psoriasis patients. On average, physicians
gave the lowest scores to the attributes of
‘‘ability to tailor dosing’’ and ‘‘mechanism of
action’’ (mean scores B 6.0).
Table 3 Demographic and clinical characteristics of par-
ticipating psoriasis patients
Sampled psoriasis
patients (n5 196)a
Severity of psoriasis symptoms at its worst
Moderate 89 (45.4%)
Severe 107 (54.6%)
Years since psoriasis diagnosis
\1 year 10 (5.1%)
1–5 years 81 (41.3%)
6–10 years 44 (22.4%)
11–20 years 30 (15.3%)
21? years 31 (15.8%)
Current treatment for psoriasis
Adalimumab 34 (17.3%)
Etanercept 32 (16.3%)
Inﬂiximab 18 (9.2%)
Ustekinumab 16 (8.2%)
Apremilast 15 (7.7%)
Secukinumab 12 (6.1%)
Doctor most frequently seen for psoriasis
Dermatologist 116 (59.2%)
Rheumatologist 32 (16.3%)
Other (i.e., PCP) 48 (24.5%)
Male 79 (40.3%)
Age
18–29 years old 27 (13.8%)
30–39 years old 82 (41.8%)
40–49 years old 39 (19.9%)
50–69 years old 43 (21.9%)
70? years old 5 (2.6%)
Ethnicity
Non-Hispanic White 155 (79.1%)
Hispanic or Latino 22 (11.2%)
Table 3 continued
Sampled psoriasis
patients (n5 196)a
Non-Hispanic Black or
African American
12 (6.1%)
Other (e.g., Asian/Paciﬁc
Islander, Native American)
7 (3.6%)
Values are count (%)
PCP primary care physician
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Stated Importance of Attributes: Patients
Patients’ stated preferences were concordant for
moderate and severe disease (maximum differ-
ence: 0.2) (Table 5). Mean ratings of safety and
efficacy metrics ranged from 6.9 to 8.2. Among
other metrics, out-of-pocket cost was rated
highly (8.0), while ratings for dosing frequency
and ROA ranged from 6.6 to 7.0. Attributes were
Table 4 Physicians: stated importance of attributes
Stated importance of treatment attributes
Mean score (standard deviation)
(15 not at all critical; 9 5 extremely critical)
Moderate psoriasis Severe psoriasis
Efﬁcacy
Overall perception of efﬁcacy 7.8 (1.4) 7.9 (1.5)
Reduction in % of BSA affected 7.8 (1.3) 8.0 (1.3)
Maintenance of response over time 7.7 (1.4) 7.8 (1.4)
Reduction in symptoms associated with lesions 7.6 (1.5) 7.7 (1.4)
Reduction in redness, thickness, and scale 7.4 (1.5) 7.5 (1.5)
Improvements in patients’ QoL 7.3 (1.9) 7.4 (1.8)
Rapidity of response after initiating treatment 6.4 (1.6) 6.7 (1.6)
Improvement based on key metrics in real-world data 6.4 (2.0) 6.4 (2.1)
Improvement based on key metrics in trial data 6.0 (2.1) 6.1 (2.2)
Safety
Overall perception of safety 8.1 (1.2) 8.1 (1.2)
Low potential for AEs based on real-world data 8.0 (1.3) 8.0 (1.3)
Low potential for AEs based on clinical trial data 7.9 (1.4) 7.9 (1.4)
Patient-speciﬁc contraindications 7.4 (1.6) 7.4 (1.6)
Low potential for tolerability issues 7.0 (1.5) 6.9 (1.5)
Other
Overall perception of performance based on
non-efﬁcacy or safety metrics
6.9 (1.7) 7.0 (1.6)
Affordable/reasonable patient out-of-pocket cost 7.8 (1.4) 7.8 (1.4)
Minimal access and coverage issues 7.6 (1.6) 7.6 (1.6)
Familiarity/experience with the therapy 7.2 (1.5) 7.3 (1.6)
Maintenance dosing frequency 6.4 (1.5) 6.4 (1.6)
ROA 6.2 (1.8) 6.1 (1.8)
Ability to tailor dosing 5.9 (1.8) 6.0 (1.8)
Mechanism of action 5.6 (1.8) 5.6 (1.9)
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consistently rated as intermediate to high
importance ([6) on the 9-point scale.
Differences in Stated Importance
of Attributes: Physicians vs. Patients
Physicians seemingly placed higher value in
objective clinical measures (e.g., reduction in %
of BSA affected), whereas patients placed higher
value in subjective measures that would most
directly impact them (QoL, signs, symptoms).
Patients rated reduction in signs (redness,
thickness, scale) and symptoms higher than
BSA, although patients and physicians had the
same numeric ratings for BSA reduction.
Patients rated QoL improvement and mainte-
nance of response higher than physicians. Dif-
ferences between physicians and patients are
clinically meaningful though not necessarily
statistically significant. However, patient-stated
preference for QoL relative to physician-stated
preference was statistically significant.
Results from Derived DCE: Relative
Importance and Importance Weights
for Moderate Psoriasis Patients (Physician
Model)
In the physician model for moderate psoriasis
(Fig. 3), dosing was the most important
Table 5 Psoriasis patients; stated importance of attributes
Stated importance of treatment attributes
Mean score (standard deviation)
(1 5 not at all critical; 95 extremely critical)
Moderate psoriasis Severe psoriasis
Efﬁcacy
Reduction in symptoms associated with lesions 8.2 (1.4) 8.1 (1.3)
Reduction in redness, thickness, and scale 8.0 (1.4) 8.1 (1.2)
Maintenance of response over time 8.0 (1.3) 8.1 (1.3)
Improvement in QoL 8.0 (1.3) 7.9 (1.6)
% reduction in BSA affected 7.8 (1.4) 8.0 (1.4)
Rapidity of response after initiating treatment 7.7 (1.4) 7.8 (1.4)
Scientiﬁc or clinical information presented by a doctor
that demonstrates efﬁcacy
7.2 (1.8) 7.3 (1.8)
Scientiﬁc or clinical information about efﬁcacy from
sources other than a doctor
6.9 (1.7) 7.0 (2.0)
Safety
Low potential for serious adverse events 8.1 (1.5) 8.1 (1.2)
Low potential for minor side effects 7.6 (1.8) 7.6 (1.5)
Other
Therapy is affordable/has reasonable out-of-pocket costs 8.0 (1.4) 8.0 (1.4)
How often you need to receive a medication 6.9 (2.1) 7.0 (2.0)
How the medication is taken (e.g., orally as a pill or tablet,
subcutaneous injection, infusion)
6.6 (2.5) 6.8 (2.4)
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attribute in driving treatment choice (RI 32%),
followed by probability of improvement mea-
sured by PASI and BSA affected after 16 weeks of
treatment (RI 26%). Safety attributes were next
highest [probability of an adverse event (RI
12%), probability of a serious adverse event (RI
10%)], but considerably lower than dosing and
efficacy. The probability of loss of response
within 1 year (RI 3%) was considered the least
important treatment attribute compared to the
others, and was the only attribute where the
level preference weights were not naturally
ordered.
Figure 4 shows the estimated importance
weights for considerations when treating mod-
erate psoriasis patients in the physician model
and 95% confidence intervals (CIs) for the seven
different treatment attributes tested in the DCE.
Physicians viewed most levels of improve-
ment in PASI and BSA as significantly different
when considering them for treatment of mod-
erate psoriasis. For the probability of PASI
75/90/100 and BSA remaining affected attri-
bute, the most valued improvement was from
the moderate level (level 2) to the high level
(level 3). There was no statistically significant
difference in physicians’ impression of the
product for moderate psoriasis if it improved
from the high level (level 3) to the very high
level (level 4). For the dosing attribute, physi-
cians viewed an IV ROA as the least appealing
compared to subQ injection in any setting or at
any tested frequency. Physicians also viewed
oral dosing as a statistically significantly pre-
ferred ROA option compared to subQ or IV
administration for treatment of moderate pso-
riasis. The model shows that physicians con-
sidered a difference in the risk of an AE of 70%
vs. 55% as significant, and differences between
all levels of probability of an SAE (10% vs. 5%,
5% vs 1%) as significant as well.
Results from Derived DCE: Relative
Importance and Importance Weights
for Severe Psoriasis Patients (Physician
Model)
In the physician model for treatment of severe
psoriasis (Fig. 5), the probability of improve-
ment measured by PASI and BSA affected after
16 weeks of treatment (RI 42%) was the most
important attribute in driving treatment choice.
Dosing frequency and format (RI 22%) ranked
as the second most important attribute and
probability of loss of response within 1 year (RI
1%) as the least important across all attributes
tested. Additionally, physicians placed a low
level of importance on safety attributes (RI of
probability of an adverse event and probability
of a serious adverse event were both 8%).
Figure 6 shows the estimated importance
weights for considerations when treating severe
psoriasis patients in the physician model and
95% confidence intervals (CIs) for the seven
different treatment attributes tested in the DCE
For probability of PASI 75/90/100 and per-
centage of BSA remaining affected, the greatest
difference was observed from the moderate level
(level 2) to the high level (level 3). There was
also a significant difference between the high
level (level 3) to the very high level (level 4),
reflecting the overall importance of efficacy in
the severe population. Within the ROA/
Fig. 3 Relative importance of attributes (moderate psori-
asis—physician model)
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location/maintenance dosing frequency attri-
bute, IV dosing was significantly less favorable
versus other ROAs; there were no significant
differences between the various subQ dosing
frequencies. For the ‘‘probability of patient
staying on therapy for 1 year’’ attribute, the
only statistically significant difference was for
increasing probability from 60% to 75%. An
increase in probability of achieving DLQI of 0 or
1 from 10% to 50% was also significant, as was a
decrease in the probability of an adverse event
from 85% to 55%. There were no statistically
significant differences between levels for prob-
ability of a serious AE and probability of loss of
response within 1 year.
Results from Derived DCE: Relative
Importance and Importance Weights
for Moderate Psoriasis Patients (Patient
Model)
In the patient model for moderate psoriasis
(Fig. 7), dosing (RI 29%) was the most impor-
tant attribute in driving treatment choice fol-
lowed closely by the number of patients with
high level of improvement in psoriasis plaques
and % BSA affected after 16 weeks of treatment
(27%). The remaining attributes, including
safety, were relatively less important compared
to ROA/location/maintenance dosing frequency
and probability of improvement. The number
of patients for whom therapy stops being
Fig. 4 Importance weights for attribute levels (moderate
psoriasis—physician model). Non-overlapping error bars
indicate statistically signiﬁcant differences across levels
within attributes at the 95% conﬁdence level. The vertical
distance between the ﬁrst and last levels within an attribute
indicates the relative importance of the attribute compared
to other attributes (i.e., the longer the line, the more
important the attribute). A larger distance between two
points would imply higher sensitivity between two levels of
the same attribute, or two levels of another attribute in the
same model. Interpretation of coefﬁcients: while each
coefﬁcient/importance weight in isolation is meaningless,
when looked at in comparison to other importance
weights it offers an estimate of the relative importance of
one attribute level over another. For example, among
physicians, an oral product that is administered at home,
twice a day, is considered about 4 times more important
than a subcutaneous injection that is administered at
home, once every 12 weeks (0.83/0.22 = 3.77). Such
comparisons can also be made across attributes
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effective within 1 year (RI 0%) was the least
important treatment attribute compared to all
others.
Figure 8 shows the estimated importance
weights for considerations when thinking of
moderate disease in the patient model and 95%
confidence intervals (CIs) for the seven different
treatment attributes tested in the DCE.
In the patient model for treatment of mod-
erate psoriasis, oral administration was statisti-
cally significantly preferred compared to any of
the subQ dosing options, and IV administration
was the least preferred among all choices. The
difference between the moderate level (level 2)
and the high level (level 3) of effectiveness was
significant and showed the greatest magnitude
of difference between levels for moderate pso-
riasis. There was no statistically significant dif-
ference between the high level (level 3) and the
very high level (level 4). The model shows that
patients considered a difference in the risk of an
adverse effect from 70% to 55% and the differ-
ence of a risk of a severe adverse effect from 5%
to 1% as significant.
Results from Derived DCE: Relative
Importance and Importance Weights
for Severe Psoriasis Patients (Patient
Model)
In the patient model for treatment of severe
psoriasis (Fig. 9), the proportion of patients with
a high level of improvement in psoriasis plaques
and BSA remaining affected (RI 36%) was the
predominant driver of treatment choice. The
other six attributes were much less important
relative to this key efficacy attribute, with the
‘‘probability that quality of life will improve
(with respect to psoriasis)’’ after 16 weeks of
treatment (RI 16%) as the second most impor-
tant. The number of patients for whom therapy
stops being effective (RI 4%) was the least
important across all attributes tested. Safety
(probability of a minor adverse effect and of a
severe adverse effect) was considered relatively
less important in the patient model for severe
psoriasis.
Figure 10 shows the estimated importance
weights for considerations when thinking of
severe disease in the patient model and 95%
confidence intervals (CIs) for the seven dif-
ferent treatment attributes tested in the
DCE.
The most meaningful differences for the
proportion of patients with improvement were
between the moderate level (level 2) and the
high level (level 3) as well as between the
high level (level 3) and the very high level
(level 4). IV administration was significantly
less preferred relative to other dosing options,
with the exception of every 4 week subQ
dosing, which ranked nearly as low as IV
administration. No difference in preference
was observed between oral and other subQ
dosing options. Relatively less importance was
placed on safety concerns for treatment of
severe disease, with only a difference of 85%
vs 70% for probability of a minor adverse
effect reaching significance. Only a difference
of 10% vs. 1% was significant for the proba-
bility of a severe adverse effect.
Fig. 5 Relative importance of attributes (severe psoriasis—
physician model)
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DISCUSSION
Comparisons of Physician-Derived
Attribute Preferences Based on Disease
Severity: Moderate vs. Severe Psoriasis
Physician preferences for treatment of moderate
and severe psoriasis were broadly consistent. For
moderate disease, physicians most heavily val-
ued dosing frequency and efficacy (improve-
ment in PASI score and BSA), almost equally.
Similarly, physicians found efficacy and dosing
frequency to be most important for choice of
treatment for severe psoriasis; however, efficacy
was nearly twice as important as dosing fre-
quency for severe disease (as compared to
treatment of moderate disease). For both mod-
erate and severe psoriasis, safety, probability of
loss of response within 1 year, and probability
of patients staying on therapy for 1 year were
less important, suggesting that physicians were
willing to trade lack of treatment durability and
safety for short-term efficacy and convenience
of dosing regimen.
Comparisons of Patient-Derived Attribute
Preferences Based on Disease Severity:
Moderate vs. Severe Psoriasis
Interestingly, the trends for attribute preference
were relatively consistent among patients
regardless of disease severity. Patients valued
efficacy and dosing frequency as the top treat-
ment attributes. For moderate disease, dosing
frequency and efficacy were almost equally
important to patients. For severe disease, effi-
cacy was more than twice as important as dos-
ing frequency and probability of improvement
in DLQI. Achieving a very high level of clinical
response was important for severe psoriasis
Fig. 6 Importance weights for attribute levels (severe
psoriasis patients—physician model). Non-overlapping
error bars indicate statistical signiﬁcant differences across
levels within attributes at the 95% conﬁdence level. The
vertical distance between the ﬁrst and last levels within an
attribute indicates the relative importance of the attribute
compared to other attributes (i.e., the longer the line, the
more important the attribute). A larger distance between
two points would imply that a higher sensitivity exists
between two levels of the same attribute, or two levels of
another attribute in the same model
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patients, as a statistically significant difference
was observed between achieving a very high
level (level 4) vs a high level (level 3) of
response. In contrast, similar findings were not
seen in the moderate patient model. Of note,
patients valued durability of treatment and
safety to a much lesser extent compared to
efficacy and dosing frequency attributes. Rela-
tive to the moderate patient model, there was
less sensitivity to varying safety levels in the
severe patient model.
Comparisons of Physician-
and Patient-Derived Attribute Preferences
The parallel DCE design for both physicians and
patients facilitates comparisons of attribute
preferences between these stakeholders. How-
ever, direct comparisons should be limited
given that the data were modeled separately.
Nonetheless, our findings suggest similarities in
preferences for treatment attributes between
physicians and patients. With consideration of
treatment for both moderate and severe
psoriasis the most and least important treat-
ment attributes were identical between physi-
cians and patients. The most important
attribute for moderate psoriasis was dosing,
while the most important attribute for severe
psoriasis was related to efficacy. This indicates
that the primary desired outcome for moderate
disease was different for that of severe disease;
specifically, in severe disease, the probability of
improvement was paramount while in moder-
ate disease attributes related to dosing fre-
quency and route of administration were
slightly more important than efficacy. Con-
versely, the least important attribute for both
physicians and patients was the probability of
loss of response within 1 year, regardless of
severity of disease. This finding suggests that
both physicians and patients were more focused
on short-term outcomes and were less con-
cerned with long-term responses despite psori-
asis being a chronic disease. Further studies are
needed to address the reasons underlying this
observation. Furthermore, amelioration of pso-
riasis symptoms correlated with a greater
improvement in QoL.
This study indicated that disease severity was
a significant driver of therapy choice for both
physicians and patients. When considering
treatment for moderate psoriasis, physicians
and patients most heavily weighted dosing
parameters. Twice-daily oral dosing was pre-
ferred by both stakeholders over IV and subQ
routes of administration, regardless of fre-
quency or location of administration. In con-
trast, for severe psoriasis, efficacy attributes were
most critical; physicians and patients preferred
treatments with a higher probability of sub-
stantial improvement. Intuitively, respondents
believed that greater efficacy is expected with
greater severity of disease. Interestingly, greater
emphasis was placed on short-term response, as
the potential for stopping therapy through 1
year or loss of effectiveness ranked low as con-
cerns. Further studies are warranted to more
fully understand why drivers of maintenance of
response (e.g., willingness to recognize psoriasis
as a chronic disease, increasingly greater num-
ber of treatment options if one fails, etc.) are
valued to a lesser extent over more short-term
efficacy.
Fig. 7 Relative importance for attributes (moderate pso-
riasis—patient model)
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Differences Between Stated Importance
and Importance from DCE
While the surveys included both stated and
derived importance exercises for treatment
attributes, relative importance (RI) values
derived from the DCE are significantly more
reliable in real-world decision-making given the
trade-offs that have to be made between attri-
butes. Stated importance levels are useful to
establish a baseline understanding, but differ-
ences between stated and derived importance
are expected, given that the latter requires one
to prioritize attributes.
Not surprisingly, discrepancies between sta-
ted importance (mean scores on a 1 [not at all
critical] to 9 [extremely critical] scale of impor-
tance) and modeled importance (i.e., derived
from the DCE) of treatment attributes were
identified. When tasked with rating the impor-
tance of various efficacy, safety, and other
factors in treatment choice, physicians and
patients tended to rate each attribute relatively
highly (C 6 on the 9-point scale). This may be
explained, in part, by there being no risk for
stating that all attributes are relatively impor-
tant and that trade-offs between attributes were
not required. However, in the DCE, trade-offs
between attributes had to be made to determine
their relative importance. Given the nature of
the two separate exercises, discrepancies
between stated importance and modeled
importance were inevitable.
There was a higher degree of alignment
between stated and derived importance from
the DCE for severe psoriasis. The stated impor-
tance of efficacy measures for moderate psoria-
sis was high for physicians and patients alike,
whereas results from the DCE suggested that
ROA is more important than efficacy. Con-
versely, the stated importance of treatment
attributes for severe psoriasis aligned with
Fig. 8 Importance weights for attribute levels (moderate
psoriasis– patient model). Non-overlapping error bars
indicate statistical signiﬁcant differences across levels
within attributes at the 95% conﬁdence level. The vertical
distance between the ﬁrst and last levels within an attribute
indicates the relative importance of the attribute compared
to other attributes (i.e., the longer the line, the more
important the attribute). A larger distance between two
points would imply that a higher sensitivity exists between
two levels of the same attribute, or two levels of another
attribute in the same model
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results for modeled (or relative) importance
from the DCE. The stated importance of various
efficacy measures was rated highly and were
consistent with probability of improvement
(PASI and BSA) from the DCE.
Strengths of the Research
and Comparisons from the Literature
Prior DCE studies for psoriasis have provided
insight into individual stakeholder preferences
for psoriasis treatments and accept-
able trade-offs between risks and benefits.
Schaarschmidt et al. [18] found that psoriasis
patients considered treatment location (e.g., at
home, outpatient clinic) and method of deliv-
ery (e.g., oral, injection) as the most important
attributes for selecting psoriasis treatments. The
relative importance of process-related attributes
(i.e., treatment location, method of delivery,
frequency, cost) were higher than for adverse
effect-related attributes. Probability of benefit
was second most important. Seston et al. [19]
observed that psoriasis patients found the
greatest benefit in low risks of skin cancer and
liver damage, and preferred treatments that
achieve moderate improvement more quickly.
Process attributes were of moderate importance.
Similar to Schaarschmidt et al. [18], our
study found that dosing frequency and effi-
cacy are the most important attributes for
psoriasis patients. As compared to other
aforementioned DCE studies, adverse events
were of secondary importance in psoriasis
treatment choice.
However, to our knowledge, our study was
unique in that it provides perspective on pref-
erences for treatment attributes for both physi-
cians and patients using a parallel DCE design.
Additionally, our study characterizes prefer-
ences for treatment attributes on the basis of
psoriasis severity (moderate versus severe). A
further strength of this research was the incor-
poration of attributes and attribute levels rele-
vant to newer agents used for treating psoriasis
in clinical practice.
Limitations with Study and Discrete
Choice Methodology
While the study design using DCE methodology
had several strengths, several limitations should
be noted. First, the analysis was limited to data
provided only by respondents, which may limit
the ability to generalize findings to broader
groups of physicians and patients. Physicians
participating in the DCE were asked to make
choices for favorability of attributes of treat-
ments for moderate and severe psoriasis at an
aggregate level rather than at an individual
patient level. As such, some considerations (e.g.,
specific patient preferences, prior treatment
history/response, and comorbidities) were not
taken into account when making treatment
choices. Additionally, respondents had to make
some assumptions for their choices based on
hypothetical circumstances (e.g., answering for
severe disease if they were classified as having
moderate disease). Lastly, implausible choice
sets (e.g., administered orally and had the
highest level of effectiveness) were not tested in
the DCE given attributes of currently available
marketed treatments.
Fig. 9 Relative importance for attributes (severe psoria-
sis—patient model)
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To ensure that the DCE had a design that
respondents could feasibly complete without
significant fatigue/burden, the numbers of
attributes and levels tested were constrained. To
achieve a feasible experimental design and
reduce correlation between variables, efficacy
(probability of improvement in PASI and % of
BSA remaining affected) and dosing-related
attributes (route of administration, setting, and
dosing frequency) were two attributes that had
multiple components. Results may have varied
if the elements were tested separately given a
different experimental design. Various other
attributes could have been included in the
design, but were excluded to ensure the task was
manageable for respondents. Such potential
attributes included, but are not limited to,
physician recommendation (patient design
only), usage of treatment by family members
(patient design only), degree of patient
engagement in self-care (physician and patient
design). Additionally, the treatment attributes
tested in the DCE were clinically focused so that
the impact of cost and patient affordability were
not included in decision-making. Future work
should consider including non-clinical and
other aforementioned attributes to understand
their impact on treatment preference.
Finally, response rates for both physician
and patient surveys were relatively low given a
large number of respondents not clicking on the
survey invite link, which could be due to a
number of reasons (e.g., lack of interest, etc.).
Shared Decision-Making Between
Physicians and Patients
Prior research indicated that shared deci-
sion-making between physicians and patients
led to greater levels of satisfaction with treat-
ment and ultimately better health outcomes,
Fig. 10 Importance weights for attribute levels (severe
psoriasis patients—patient model). Non-overlapping error
bars indicate statistical signiﬁcant differences across levels
within attributes at the 95% conﬁdence level. The vertical
distance between the ﬁrst and last levels within an attribute
indicates the relative importance of the attribute compared
to other attributes (i.e., the longer the line, the more
important the attribute). A larger distance between two
points would imply that a higher sensitivity exists between
two levels of the same attribute, or two levels of another
attribute in the same model
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particularly for chronic conditions such as pso-
riasis [14–17, 22]. Knowing that physicians and
patients may have similar preferences for attri-
butes of treatment could enable patients to
more readily voice their opinion and be an
active participant in treatment decision-mak-
ing. From the physician’s perspective, under-
standing similarities in treatment preferences
may encourage greater proactive engagement of
patients in making shared decisions [17]. Taken
together, findings from this study could help
promote more transparent and meaningful dis-
cussions on the advantages and disadvantages
of therapeutic choices, and lead to greater
patient involvement in treatment selection in
partnership with their treating physician.
CONCLUSIONS
This study provides insight into treatment
selection by physicians and patients by measur-
ing stated and derived preferences for attributes
of treatments for both moderate and severe pso-
riasis. A greater understanding of attribute pri-
oritization during treatment selection for both
stakeholders may improve the quality and fre-
quency of shared decision-making. The holistic
and comprehensive presentation of information
on the attributes of a given treatment, rather
than focusing only on specific attributes in iso-
lation, could enhance patient-centered deci-
sion-making, and potentially reduce bias
introduced by physicians’ assumptions regard-
ing patient preferences. Comprehensive educa-
tion regarding treatment attributes may help
minimize the influence of subjective biases and
facilitate appropriate and patient-centered
treatment selection in psoriasis.
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